# PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)

> **NCT00958438** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 248 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** Placebo
- **DRUG:** Rilonacept
- **DRUG:** Rilonacept

## Key facts

- **NCT ID:** NCT00958438
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2017-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00958438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00958438, "PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00958438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*